Zanubrutinib CLL: 5-Year Efficacy & Response Data
News Context
At a glance
Zanubrutinib demonstrates remarkable efficacy in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL),particularly in patients with del(17p) mutations. This groundbreaking report unveils five-year data from the SEQUOIA study, revealing a 72.2% progression-free survival rate, solidifying zanubrutinib’s role as a potent CLL treatment. The article highlights key findings, including common side effects and the drug’s mechanism as a BTK inhibitor.news Directory 3 provides a comprehensive overview of this crucial advancement in hematology, showcasing zanubrutinib’s sustained impact. Discover what’s next in innovative cancer therapies.